32
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Determinants of Highly Active Antiretroviral Therapy Duration in HIV-1-Infected Children and Adolescents in Madrid, Spain, from 1996 to 2012

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives

          To investigate the duration of sequential HAART regimens and predictors of first-line regimen discontinuation among HIV-1 vertically infected children and adolescents.

          Design

          Multicentre survey of antiretroviral-naïve patients enrolled in the HIV-Paediatric Cohor,t CoRISpeS-Madrid Cohort, Spain.

          Methods

          Patients with a follow-up of ≥1 month spent on HAART, with available baseline CD4 count and HIV-viral load (VL) were included. Time spent on sequential HAART regimens was estimated and multivariable regression was used to identify predictors of time to first-line regimen discontinuation.

          Results

          104 patients were followed for a median 8 years after starting HAART among 1996–2012; baseline %CD4 was 21.5 (12.3–34.0)and viral load was 5.1 (4.6–5.6) log 10 copies/mL. Patients received a mean of 1.9 regimens. Median time on first-line HAART (n = 104) was 64.5 months; second HAART (n = 56) 69.8 months; and third HAART (n = 21) 66.5 months. Eleven (11%) patients were lost to follow-up while on first-line HAART and 54% discontinued (cumulative incidence of 16% and 38% by 1 and 3-year, respectively). The main predictor of first-line regimen discontinuation was suboptimal adherence to antiretrovirals (AHR: 2.60; 95% CI: 1.44–4.70).

          Conclusions

          Adherence to therapy was the main determinant of the duration of the first-line HAART regimen in children. It is important to identify patients at high risk for non-adherence, such as very young children and adolescents, in provide special care and support to those patients.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found

          Antiretroviral treatment for children with peripartum nevirapine exposure.

          Single-dose nevirapine is the cornerstone of the regimen for prevention of mother-to-child transmission of human immunodeficiency virus (HIV) in resource-limited settings, but nevirapine frequently selects for resistant virus in mothers and children who become infected despite prophylaxis. The optimal antiretroviral treatment strategy for children who have had prior exposure to single-dose nevirapine is unknown. We conducted a randomized trial of initial therapy with zidovudine and lamivudine plus either nevirapine or ritonavir-boosted lopinavir in HIV-infected children 6 to 36 months of age, in six African countries, who qualified for treatment according to World Health Organization (WHO) criteria. Results are reported for the cohort that included children exposed to single-dose nevirapine prophylaxis. The primary end point was virologic failure or discontinuation of treatment by study week 24. Enrollment in this cohort was terminated early on the recommendation of the data and safety monitoring board. A total of 164 children were enrolled. The median percentage of CD4+ lymphocytes was 19%; a total of 56% of the children had WHO stage 3 or 4 disease. More children in the nevirapine group than in the ritonavir-boosted lopinavir group reached a primary end point (39.6% vs. 21.7%; weighted difference, 18.6 percentage-points; 95% confidence interval, 3.7 to 33.6; nominal P=0.02). Baseline resistance to nevirapine was detected in 18 of 148 children (12%) and was predictive of treatment failure. No significant between-group differences were seen in the rate of adverse events. Among children with prior exposure to single-dose nevirapine for perinatal prevention of HIV transmission, antiretroviral treatment consisting of zidovudine and lamivudine plus ritonavir-boosted lopinavir resulted in better outcomes than did treatment with zidovudine and lamivudine plus nevirapine. Since nevirapine is used for both treatment and perinatal prevention of HIV infection in resource-limited settings, alternative strategies for the prevention of HIV transmission from mother to child, as well as for the treatment of HIV infection, are urgently required. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT00307151.).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1.

            Combination therapy including protease inhibitors has been shown to be effective in treating adults infected with human immunodeficiency virus type 1 (HIV-1), but there are only limited data regarding the treatment of children and adolescents. A cohort of 1028 HIV-1-infected children and adolescents, from birth through 20 years of age, who were enrolled in research clinics in the United States before 1996 was followed prospectively through 1999. We used proportional-hazards regression models to estimate the effect on mortality of combination therapy including protease inhibitors. Seven percent of the subjects were receiving combination therapy including protease inhibitors in 1996; by 1999, 73 percent were receiving such therapy. In univariate analyses, a higher base-line percentage of lymphocytes that were CD4-positive, a higher weight for age, a higher height for age, black race, Hispanic ethnic background, younger age, and perinatally acquired infection were associated with a longer median time to the initiation of this type of therapy (P<0.001). After adjustment for covariates, the differences among racial and ethnic groups in the time to initiation were not statistically significant. Mortality declined from 5.3 percent in 1996 to 2.1 percent in 1997, 0.9 percent in 1998, and 0.7 percent in 1999 (P for trend <0.001). There were reductions in mortality in all subgroups defined according to age, sex, percentage of CD4+ lymphocytes, educational level of the parent or guardian, and race or ethnic background. In adjusted analyses, the initiation of combination therapy including protease inhibitors was independently associated with reduced mortality (hazard ratio for death, 0.33; 95 percent confidence interval, 0.19 to 0.58; P<0.001). The use of combination therapy including protease inhibitors has markedly reduced mortality among children and adolescents infected with HIV-1.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The Spanish HIV BioBank: a model of cooperative HIV research

              Background The collection of samples from HIV-infected patients is the beginning of the chain of translational research. To carry out quality research that could eventually end in a personalized treatment for HIV, it is essential to guarantee the availability, quality and traceability of samples, under a strict system of quality management. Methods The Spanish HIV BioBank was created with the objectives of processing, storing and providing distinct samples from HIV/AIDS patients, categorized according to strictly defined characteristics, free of charge to research projects. Strict compliance to ethical norms is always guaranteed. Results At the moment, the HIV BioBank possesses nearly 50,000 vials containing different prospective longitudinal study sample types. More than 1,700 of these samples are now used in 19 national and international research projects. Conclusion The HIV BioBank represents a novel approach to HIV research that might be of general interest not only for basic and clinical research teams working on HIV, but also for those groups trying to establish large networks focused on research on specific clinical problems. It also represents a model to stimulate cooperative research among large numbers of research groups working as a network on specific clinical problems. The main objective of this article is to show the structure and function of the HIV BioBank that allow it to very efficiently release samples to different research project not only in Spain but also in other countries.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS One
                PLoS ONE
                plos
                plosone
                PLoS ONE
                Public Library of Science (San Francisco, USA )
                1932-6203
                2014
                1 May 2014
                : 9
                : 5
                : e96307
                Affiliations
                [1 ]Instituto de Investigação do Medicamento (iMed. ULisboa), Faculty of Pharmacy, The University of Lisbon, Lisbon, Portugal
                [2 ]Hospital General Universitario “Gregorio Marañón” and Instituto de Investigación Sanitaria “Gregorio Marañón”, Madrid, Spain. Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
                [3 ]Unidad de Investigación, Fundación para la Investigación Biomédica, Hospital General Universitario “Gregorio Marañón”, Madrid, Spain
                [4 ]Servicio Infecciosas Infantil, Hospital Universitario “La Paz”, Madrid, Spain
                [5 ]Servicio de Pediatría, Hospital Universitario “Carlos III”, Madrid, Spain
                [6 ]Servicio de Pediatría, Hospital General Universitario “Gregorio Marañón”, Madrid, Spain
                [7 ]Servicio de Pediatría, Hospital Universitario de Getafe, Madrid, Spain
                [8 ]Center of Interdisciplinary Investigation Egas Moniz (CiiEM), Institute of Health Sciences Egas Moniz, Caparica, Portugal
                University of Texas Health Science Center San Antonio Texas, United States of America
                Author notes

                Competing Interests: The authors have declared that no competing interests exist.

                Conceived and designed the experiments: MIDJ FJC CP MAM. Performed the experiments: CP FJC SJDO VB. Analyzed the data: CP VB JMB. Contributed reagents/materials/analysis tools: MJM MLN JTR NT. Wrote the paper: CP VB MIDJ MAM.

                Article
                PONE-D-13-45881
                10.1371/journal.pone.0096307
                4006876
                24788034
                63b4ff7e-6b75-4e65-aaa2-6d5deaf4a25b
                Copyright @ 2014

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 31 October 2013
                : 7 April 2014
                Page count
                Pages: 6
                Funding
                This work was supported by grants provided by the Fondo de Investigación de Sanidad en España (FIS) [grant numbers PI11-00888, PS09/02029, and PI13/02016], Red Española de Investigación en SIDA (RIS) [grant numbers RETIC RD06/0006/0035 RD12-0017-0037; RD06/0006/0021, RD12/0017/0029 and RD09/0076/00103], “Fundación para la Investigación y la Prevención del Sida en España” (FIPSE), Comunidad de Madrid [grant numbers, S-2010/BMD-2351, S-2010/BMD-2332], PENTA and Fundación Eugenio Rodríguez Pascual and grants PTDC/SAU-FAR/115290/2009 and PTDC/SAU-EPI/122400/2010 from Fundação para a Ciência e Tecnologia (FCT) ( http://www.fct.pt), Portugal. Claudia Palladino is supported by the Portuguese Fundação para a Ciência e Tecnologia (FCT) (SFRH/BPD/77448/2011). Verónica Briz is supported by the Spanish Fondo de Investigación Sanitaria (Sara Borrell CD09/00433. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article
                Biology and Life Sciences
                Immunology
                Microbiology
                Medical Microbiology
                Microbial Pathogens
                Viral Pathogens
                Immunodeficiency Viruses
                HIV
                Medicine and health sciences
                Diagnostic medicine
                HIV diagnosis and management
                Health Care
                Health Care Policy
                Child and Adolescent Health Policy
                Pediatrics
                Child Health
                Urology
                Genitourinary Infections
                Public and occupational health
                Preventive medicine
                HIV prevention
                Infectious Diseases
                Viral Diseases
                Women's Health
                Obstetrics and Gynecology

                Uncategorized
                Uncategorized

                Comments

                Comment on this article